Xintela AB engages in the development of pharmaceutical products. Its technology include XINMARK, which provides a means to detect certain tumour cells and to target treatment to the cells in order to slow tumour growth. The firm is also in the process of development of XACT, used in the quality assurance of methods and cells in the company’s own development activities for stem cell products. The company was founded by Evy Lundgren-Akerlund and Rickard Mosell in 2009 and is headquartered in Lund, Sweden.

ISTO Technologies, Inc., an orthobiologics company, develops biologic products to regenerate and restore function to damaged cartilage and bone. It offers InQu, a resorbable bone graft extender and substitute; NuQu, a cell-based injectable therapy for disc regeneration; and DeNovo ET, an engineered cartilage implant for the repair and regeneration of knee cartilage. The company provides its products through distributors. ISTO Technologies, Inc. was founded in 1997 and is based in St. Louis, Missouri.

Part of Smith & Nephew plc, T.J. Smith & Nephew Ltd. is a British company located in Hull that manufactures healthcare products. It was founded in 1907. On July 01, 1999 Robinson Healthcare Group Ltd. acquired T.J. Smith & Nephew Ltd. from Smith & Nephew plc for $22.60 million.\nThe company says this about itself: The principal activity of the company is he design. development manufacture and sale of Advanced medical devices.

Shaanxi Ruisheng Biotechnology Co., Ltd., established on 2008-03-12, Business scope includes general items:Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;R&D and application of cell technology;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Sales of hygiene products and single-use medical products;Cosmetics Wholesale;Cosmetics Retail;Technology Import and Export.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;Production of hygiene products and single-use medical products.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results)

Develops human-based tissue products for therapeutic applications

Zimmer, Inc. provides joint replacement solutions. The firm products include trauma and dental implants and orthopaedic surgical products. The company was founded in 1927 and is headquartered in Warsaw, IN.

Meiyinmei Biogenetic Engineering (Shanghai) Co., Ltd, established on 2020-08-20, Business scope includes general items:artificial intelligence,healthy,the medical,Technology development in the field of biotechnology,Technical Services,technical consulting,technology transfer;Socioeconomic Advisory Services;Corporate Image Planning;marketing planning;Organize cultural and artistic exchange activities;Conference and Exhibition Services;fitness and leisure activities;Etiquette service;software development;Cosmetics Wholesale;Cosmetics Retail;General merchandise sales;Sales of Class I Medical Devices;Professional Design Services;literary creation;Medical Research and Experimental Development;Import and export;Technology Import and Export.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Smith & Nephew PLC designs, manufactures and markets orthopedic devices, sports medicine and ENT technologies, and wound-care solutions. Slightly more than 40% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is a sports medicine and ENT. The remaining 27% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Shandong Freda Pharmaceutical Group Co. Ltd., a subsidiary of Province of Shandong, is a Chinese company that manufactures pharmaceutical products. Lushang Freda Pharmaceutical Co., Ltd. acquired Shandong Freda Pharmaceutical Group Co. Ltd. from Shandong Commercial Group Co., Ltd. on December 31, 2018 for $153.09 million.

Peking University Third Hospital is a private company headquartered in Beijing, China, that operates as a clinic.

CellSeed Inc. develops regenerative medicine products. It operates through the Cell Sheet Regenerative Medicine and Intelligent Regenerative Medicine Support segments. The Cell Sheet Regenerative Medicine segment provides research, development, marketing, and sale of epithelial cell sheet for corneal and esophageal regeneration; regenerated cardiac patch to treat heart diseases; cell sheet for periodontal tissue regeneration; and regenerated cartilage sheet for the treatment of osteoarthritis. The Regenerative Medicine Support segment conducts research and development, manufacturing, and sales of temperature-responsive cell culture equipment. The company was founded by Yukio Hasegawa on May 9, 2001 and is headquartered in Tokyo, Japan.